Trial reportProceedings of the National Academy of Sciences of the United States of America2022
Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety.Immunologic research · 2025Pooled it
- Pooled it
- Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.The Cochrane database of systematic reviews · 2024Pooled it
- Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.Clinical pharmacology and therapeutics · 2026Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Maternal RSV vaccination: clinical efficacy, safety, and global policy considerations: a systematic review.Journal of pharmaceutical policy and practice · 2026Review
- Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008-2018.The Journal of infectious diseases · 2025Article
- Antibiotic use attributable to RSV infections during infancy-an international prospective birth cohort study.The Journal of antimicrobial chemotherapy · 2025Observational
- Prevention of respiratory syncytial virus disease across the lifespan in Italy.Pneumonia (Nathan Qld.) · 2025Review
- General practice antibiotic prescriptions attributable to respiratory syncytial virus by age and antibiotic class: an ecological analysis of the English population.The Journal of antimicrobial chemotherapy · 2025Article
- Infectious diseases burden and antibiotic prescribing patterns among primary care patients in Harare, Zimbabwe - a cross-sectional analysis.PLOS global public health · 2025Article
- Global trends in antibiotic consumption during 2016-2023 and future projections through 2030.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Advanced technologies for the development of infectious disease vaccines.Nature reviews. Drug discovery · 2024Review
- Outpatient respiratory syncytial virus infections and novel preventive interventions.Current opinion in pediatrics · 2024Review
- Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians.Vaccines · 2023Review
- Burden of respiratory syncytial virus diseases among under 5 children in Sub-Saharan Africa:Heliyon · 2023Article
- RETRACTED: Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward.Antibiotics (Basel, Switzerland) · 2023Article
- [Respiratory viral infections : Under special consideration of severe acute respiratory syndrome coronavirus 2 and influenza viruses].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Review
- New Interventions to Prevent Respiratory Syncytial Virus Disease in Infants-Time for Equitable Global Access.American journal of respiratory and critical care medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SignificanceStrategies to reduce consumption of antimicrobial drugs are needed to contain the growing burden of antimicrobial resistance. Respiratory syncytial virus (RSV) is a prominent cause of upper and lower respiratory tract infections, as a single agent and in conjunction with bacterial pathogens, and may thus contribute to the burden of both inappropriately treated viral infections and appropriately treated polymicrobial infections involving bacteria. In a double-blind, randomized, placebo-controlled trial, administering an RSV vaccine to pregnant mothers reduced antimicrobial prescribing among their infants by 12.9% over the first 3 mo of life. Our findings implicate RSV as an important contributor to antimicrobial exposure among infants and demonstrate that this exposure is preventable by use of effective maternal vaccines against RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.